Evidence map›Paper›PMID 29666985›Full record

ArticleJournal of neurology2018

Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.

Alexandra S Kocsik, David E Klein, Maryana Liedke, Ulrike W Kaunzner, Nancy M Nealon, Susan A Gauthier, Timothy Vartanian, Jai S Perumal

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandra S KocsikDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0001-8828-616X
David E KleinTouro College of Osteopathic Medicine, 60 Prospect Avenue, Middletown, NY, 10940, USA.ORCID http://orcid.org/0000-0003-4590-4815
Maryana LiedkeDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0003-3020-201X
Ulrike W KaunznerDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0001-9449-7369
Nancy M NealonDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0003-4133-7198
Susan A GauthierDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0002-4015-1781
Timothy VartanianDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0002-1794-9963
Jai S PerumalDivision of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA. jsp9007@med.cornell.edu.ORCID http://orcid.org/0000-0001-8174-3305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate a single-course treatment with alemtuzumab in patients with relapsing-remitting multiple sclerosis.

methodsWe performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients' first dose of alemtuzumab and were tracked until the time of analysis.

resultsIn the 2 years prior to first dose of alemtuzumab, 82.8% of the 29 patients had a new lesion on MRI and/or a clinical relapse, with an ARR of 0.67. In the mean 24.7 month follow-up after the first dose of alemtuzumab, 17.2% of patients displayed new disease activity and the ARR was 0.08. 4 out of 5 patients who relapsed did so within 12 month post-first infusion and received a second dose. Of the 24 patients who did not relapse, 8 received a second dose at 1 year and 16 did not. 5 out of all 29 patients developed thyroid disorder.

conclusionsGiven that 96% of patients who did not relapse in the first 12 months following the initial dose of alemtuzumab remained relapse-free regardless of receiving a second course of drug, our data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab. With further study, these data could support modification of the current therapy regimen.

Indexed as

AdultAlemtuzumabDisability EvaluationDisease ProgressionFemaleFollow-Up StudiesHumansImmunologic FactorsMagnetic Resonance ImagingMaleMultiple Sclerosis, Relapsing-RemittingRemission InductionRetrospective StudiesTreatment OutcomeAlemtuzumabImmunologic FactorsAlemtuzumabDisease-modifying therapyMultiple sclerosisRelapse

Identifiers

PMID29666985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.